On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.
Hearing Loss

DFNA2 (progressive, KCNQ4)

DFNA2 is a type of inherited hearing loss known as autosomal dominant non-syndromic sensorineural hearing loss. It typically affects both ears and gradually progresses, often leading to significant hearing impairment by middle age.

Autosomal dominant Hearing Loss OMIM:600101
Rare
Prevalence
Population estimate
50%
Inheritance
Autosomal dominant - each child of a parent who has the variant has a 50% chance of inheriting it
1
Associated genes
KCNQ4

Overview

DFNA2 is a genetic condition characterised by progressive hearing loss that usually begins in early adulthood. The term DFNA stands for 'dominant familial non-syndromic sensorineural hearing loss', meaning it is inherited in an autosomal dominant pattern, affects hearing directly without other major health problems (non-syndromic), and involves the inner ear (sensorineural). Individuals with DFNA2 often experience a gradual decline in their ability to hear, particularly high-pitched sounds [PMID:10377313].

Unlike some forms of hearing loss present from birth, DFNA2 typically manifests later in life, often between the ages of 10 and 30 years. The progression rate can vary, but most affected individuals find their hearing loss becomes functionally significant, requiring intervention, as they age [PMID:10377313]. It affects both ears (bilateral) and is symmetrical, meaning both ears are usually affected to a similar degree.

Symptoms & clinical features

The primary symptom of DFNA2 is hearing loss that typically starts subtly and worsens over time. This is often first noticed as difficulty hearing high-frequency sounds, such as female or children's voices, or distinguishing speech in noisy environments [PMID:10377313]. As the condition progresses, the range of frequencies affected expands, leading to more profound hearing impairment across the sound spectrum.

Initially, individuals might find themselves turning up the volume of televisions or struggling in group conversations. Over the years, the hearing loss can become severe to profound. Tinnitus, a ringing or buzzing sound in the ears, may sometimes be experienced alongside the hearing loss, though this is not a universal symptom of DFNA2 [PMID:10377313].

Video: Genetics 101

Affected organs

DFNA2 primarily affects the inner ear, specifically the hair cells within the cochlea. These delicate sensory cells are crucial for converting sound vibrations into electrical signals that the brain interprets as sound. In DFNA2, the progressive damage to these hair cells leads to sensorineural hearing loss. No other major body systems or organs are typically affected by DFNA2, categorising it as a non-syndromic form of hearing loss.

Multiple body systems
Multiple body systems
Systemic involvement
Cellular impact
Cellular impact
Mechanism at cellular level

Risks & severity

The severity of hearing loss in DFNA2 can vary between individuals, even within the same family, but it is typically progressive. While some people may only experience moderate hearing loss, others can develop severe to profound hearing impairment, requiring significant support. The age of onset usually falls within adolescence to early adulthood, generally from 10 to 30 years old, with noticeable decline increasing over subsequent decades.

There is no cure for DFNA2, and the hearing loss is irreversible. However, appropriate management can significantly improve quality of life. The condition does not generally impact life expectancy or cause other health complications beyond hearing impairment.

Genetic causes

DFNA2 is caused by genetic changes (variants) in the KCNQ4 gene. The KCNQ4 gene provides instructions for making a protein that forms a specific type of potassium channel. These channels are vital for the normal function of the outer hair cells in the cochlea of the inner ear.

The KCNQ4 potassium channels help regulate the electrical signals within hair cells, which is essential for our ability to hear. Pathogenic variants in KCNQ4 disrupt the proper functioning of these channels, leading to the progressive degeneration and loss of cochlear hair cells, resulting in the characteristic sensorineural hearing loss seen in DFNA2 [PMID:9562579].

  • KCNQ4
    potassium voltage-gated channel subfamily Q member 4

Inheritance pattern

DFNA2 is inherited in an autosomal dominant pattern. This means that a person only needs to inherit one copy of the altered KCNQ4 gene from either parent to develop the condition. If one parent has DFNA2, there is a 50% chance with each pregnancy that their child will also inherit the condition. This inheritance pattern explains why the condition often appears in successive generations within a family.

Individuals who inherit the altered gene will typically develop the hearing loss, although the specific age of onset and rate of progression can sometimes vary. The condition affects males and females equally. Family members considering starting a family may wish to discuss the inheritance pattern and risks with a genetic counsellor.

♀ Affected parent 1 altered copy ♂ Unaffected parent 2 typical copies Affected Unaffected Unaffected Affected Affected Carrier Unaffected Circles = females · Squares = males

Each child of an affected parent has a 50% chance of inheriting the pathogenic variant, regardless of sex.

Diagnosis & testing

Diagnosis of DFNA2 is typically based on clinical assessment, including audiometric testing that shows progressive, bilateral, high-frequency sensorineural hearing loss, along with a family history consistent with autosomal dominant inheritance. Genetic testing is used to confirm the diagnosis by identifying a pathogenic variant in the KCNQ4 gene.

In the UK, genetic testing for inherited hearing loss, including DFNA2, is available through the NHS Genomic Medicine Service. A clinical geneticist or an audiovestibular medicine specialist may refer individuals for testing, often following an R-code testing pathway. This testing can help to provide a precise diagnosis, inform prognosis, and allow for appropriate genetic counselling for the individual and their family.

Management & lifestyle

While there is currently no cure for the progressive hearing loss associated with DFNA2, various management strategies can help improve communication and quality of life. The primary interventions focus on amplifying sound and supporting communication.

Hearing aids are often the first line of intervention as hearing loss progresses, and they can be very effective in managing the symptoms. For individuals with severe to profound hearing loss, cochlear implants may be a suitable option. Ongoing audiological assessment and support from an audiologist are crucial to monitor hearing changes and adjust devices as needed. Genetic counsellors can provide essential information on the condition's inheritance, discuss family planning, and offer emotional support.

UK care pathway

In the UK, individuals with suspected genetic hearing loss can access diagnosis and support through the NHS Genomic Medicine Service. If a genetic condition like DFNA2 is suspected based on symptoms and family history, a healthcare professional, such as an Ear, Nose, and Throat (ENT) consultant or an Audiologist, can refer to Clinical Genetics services. Genetic testing for inherited hearing loss is available under specific NHS national genomic testing directories (R-codes). Following a confirmed diagnosis, individuals are supported by a multidisciplinary team, potentially including audiologists and genetic counsellors, to manage their condition and understand its implications.

Frequently asked questions

What does 'non-syndromic' mean in DFNA2?

'Non-syndromic' means that the hearing loss is the only major health problem associated with DFNA2. It typically does not cause other medical issues or affect other body systems, distinguishing it from syndromic forms of hearing loss which occur as part of a broader set of symptoms.

When does DFNA2 usually start?

DFNA2 typically begins in early adulthood, often between 10 and 30 years of age. The hearing loss starts subtly and worsens gradually over many years, affecting high pitches first before progressing to a wider range of frequencies.

Can DFNA2 be treated?

While there is no cure for the underlying genetic cause of DFNA2, its symptoms can be effectively managed. Hearing aids are commonly used, and for more profound hearing loss, cochlear implants can be a suitable option to significantly improve hearing and communication.

If I have DFNA2, will my children get it?

Because DFNA2 is inherited in an autosomal dominant pattern, if you have the condition, there is a 50% chance that any child you have will also inherit the altered KCNQ4 gene and develop DFNA2. Genetic counselling is recommended to discuss these risks in detail.

Is DFNA2 a common condition?

DFNA2 is considered a rare condition. While the exact prevalence is not well established, genetic forms of hearing loss collectively affect a significant number of people, but specific types like DFNA2 are individually less common.

Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor.